Phase 3, Multi-center, double-blind, randomized, parallel group study of the efficacy, safety, and tolerability of fixed combination torcetrapib (CP-529,414)/Atorvastatin administered orally, once daily (QD) for six months, compared with maximally tolerated Atorvastatin therapy alone, in subjects with heterozygous familial hypercholesterolemia.

Registry ID

EUCTR2004-004269-14

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Pfizer AB

Start date

2005-02-18

Last update

2026-08-16

Conditions

• Heterozygous Familial Hypercholesterolemia

Summary

The primary objective of this study is to demonstrate the efficacy of fixed combination torcetrapib/atorvastatin in lowering LDL-C, raising levels of HDL-C and favorably altering the levels of other lipid parameters and biomarkers, when compared to atorvastatin alone, in subjects with heFH.

Locations

• , , Sweden
• , , Denmark
• , , Iceland

Related clinical trials

• A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
• Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, with Heterozygous Familial Hypercholesterolemia on Stable Diet and Oral Lipid-Lowering Therapy (LIBerate-Kids)
• Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease
• A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
• Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia

View on source registry